Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action - GUTS

Event

Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action - GUTS

About Fractyl Health, Inc.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

More from GUTS